活跃癌症患者ST升高心肌梗塞后缺血和出血风险:全国性研究
Mohamed Dafaalla1, Francesco Costa2,3,4, Haibo Jia5
1Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele Rd, Keele ST5 5BG, UK.
European heart journal open
|March 12, 2025
概括
经历ST升高心肌梗塞 (STEMI) 的癌症患者面临更高的重大出血风险,但不会再次发病. 管理出血并发症对于改善这些复杂病例的结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 在癌症患者中,ST升高心肌梗塞 (STEMI) 的治疗因血栓和出血事件的风险增加而复杂化.
- 与非癌症患者相比,癌症患者往往出现更多的并发症,并且接受的侵袭性治疗少于非癌症患者.
研究的目的:
- 调查STEMI患者有或没有活跃癌症的重大出血和再发病的比较风险.
- 为癌症STEMI患者的临床管理策略提供信息.
主要方法:
- 一项国家队列研究将英国心肌梗塞国家审计项目和从2005年1月到2019年3月的医院病例统计数据联系起来.
- 确定了322,776例STEMI入院病例,其中7050例 (2.2%) 被诊断为活跃癌症.
- 主要结局是严重出血和1年后再次发病,使用生存分析进行分析.
主要成果:
- 癌症患者年龄较大,并患上更多的并发症,并且接受的侵袭性手术 (血管造影,PCI) 和双重抗血小板治疗较少.
- 在癌症患者中,严重出血的发生率显著高于癌症患者 (6.5%对3.5%).
- 在调整后,癌症患者的复发风险类似 (SHR 1.10),但严重出血风险增加了50% (SHR 1.49).
结论:
- 与没有癌症的患者相比,患有癌症的STEMI患者患大出血的风险明显更高.
- 在癌症和非癌症STEMI患者中,再次发病的风险是可比的.
- 减轻出血风险的策略对于改善癌症STEMI患者的治疗结果至关重要.
更多相关视频
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
11.1K
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
4.0K
相关概念视频
02:30Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
01:17Ischemic Heart Disease: Overview
1.1K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
76
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
76